Science Explorer Back to mapMap
Discussion
Researcher · Bayer (Germany) · Germany

Oliver Politz

Oliver Politz publishes mostly in Molecular Biology, Pulmonary and Respiratory Medicine and Immunology, on topics such as PI3K/AKT/mTOR signaling in cancer, Fibroblast Growth Factor Research and Lymphoma Diagnosis and Treatment.

ORCID 0000-0002-0272-6249 OpenAlex
World rank
#465,348
of 7,710,434 ranked researchers
Rank in Germany
#22,822
of 364,343
Works
110
Citations
3k
Citations per work
27.0
h-index
24
i10-index 33Top 24% in Molecular Biology
Oliver Politz

What does Oliver Politz research?

Oliver Politz's work is mostly in Biochemistry, Genetics and Molecular Biology (34%), Medicine (27%), Immunology and Microbiology (11%).

Life Sciences: 49 works · 44.5% of their workBiochemistry, Genetics and Molecular Biology: 37 works · 33.5% of their workMolecular Biology: 27 works · 24.9% of their workCancer Research: 9 works · 8.6% of their workImmunology and Microbiology: 12 works · 11.0% of their workImmunology: 12 works · 11.0% of their workEverything else: 31 works · 28.2% of their workHealth Sciences: 30 works · 27.3% of their workMedicine: 30 works · 27.3% of their workPulmonary and Respiratory Medicine: 13 works · 11.5% of their workOncology: 12 works · 10.5% of their workPathology and Forensic Medicine: 6 works · 5.3% of their workTHEIR WORKOliver Politz110works
Life Sciences44%Health Sciences27%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology3733.5%
    2. Immunology and Microbiology1211.0%
  2. Everything else3128.2%
    1. Medicine3027.3%
  1. 1Molecular Biology25% of their works
  2. 2Pulmonary and Respiratory Medicine12% of their works
  3. 3Immunology11% of their works
  4. 4Oncology10% of their works
  5. 5Cancer Research9% of their works
  6. 6Pathology and Forensic Medicine5% of their works

Research topics

Which keywords describe Oliver Politz's research?

The keywords of their largest research topics: Cancer, Signaling, Rituximab, mTOR, PI3K/AKT pathway, Classification, FGF21 and Fibroblast Growth Factor.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 19 words, with their numbers
  1. Cancer232 topics
  2. Signaling232 topics
  3. Rituximab162 topics
  4. PI3K/AKT pathway141 topic
  5. mTOR141 topic
  6. Classification91 topic
  7. FGF2191 topic
  8. Fibroblast Growth Factor91 topic
  9. Lymphoma91 topic
  10. HIF-181 topic
  11. Warburg Effect81 topic
  12. Biotechnological Applications71 topic
  13. Breast Cancer71 topic
  14. CDK4/6 Inhibitors71 topic
  15. Chronic Lymphocytic Leukemia71 topic
  16. Enzymatic Hydrolysis71 topic
  17. Genomic Aberrations71 topic
  18. Microbial Enzymes71 topic
  19. Pretreatment71 topic

Where does Oliver Politz work?

Oliver Politz's main affiliation in the publication record is Bayer (Germany), Germany.

How many publications and citations does Oliver Politz have?

OpenAlex counts 110 works and 2,967 citations for Oliver Politz, an h-index of 24, ranking #465,348 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Oliver Politz. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.